FDA clears Aprea Therapeutic’s Investigational New Drug (IND) application (IND 169359) for oral WEE1 Inhibitor, APR-1051
Aprea to initiate the Phase 1 ACESOT-1051 trial. Learn more

Collaboration Expands Aprea’s Capabilities—and Our Thinking


Working closely with respected institutions and precision medicine leaders gives us greater access to state-of-the-art facilities, novel approaches and new ideas in DDR-targeted therapy.

Partner with Aprea

Are you interested in joining us in our mission to revolutionize cancer treatment?

Contact us at [email protected] to explore the possibilities.